MEK Inhibitor News and Research

RSS
PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

Promising results for dabrafenib in advanced melanoma

Promising results for dabrafenib in advanced melanoma

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma third quarter revenue increases to $19.1M

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

Melanoma drug makes pre-existing cells with RAS mutation grow into skin squamous cell cancers

Melanoma drug makes pre-existing cells with RAS mutation grow into skin squamous cell cancers

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC

Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Merck, sanofi-aventis enter global cancer research and development agreement

Merck, sanofi-aventis enter global cancer research and development agreement

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Melanoma Research Alliance announces grant to support six research programs

Melanoma Research Alliance announces grant to support six research programs

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.